Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia (Q37898699)

25 August 2017

1 reference

title

Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia (English)

1 reference

25 August 2017

1 reference

1 reference

Theodosios D. Filippatos

object named as

Theodosios D Filippatos

series ordinal

1

0 references

Moses Elisaf

object named as

Moses S Elisaf

series ordinal

2

0 references

language of work or name

English

0 references

publication date

8 July 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

1 reference

25 August 2017

12

1 reference

25 August 2017

1945-1958

1 reference

25 August 2017

12

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Clinical outcomes in statin treatment trials: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Primary cardiovascular events and serum lipid levels in elderly Japanese with hypercholesterolemia undergoing 6-year simvastatin treatment: a subanalysis of the Japan lipid intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effects of long-term treatment with simvastatin on some hemostatic parameters in continuous ambulatory peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Lipoprotein-associated phospholipase A₂ activity and mass in relation to vascular disease and nonvascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Simvastatin reduces expression and activity of lipoprotein-associated phospholipase A(2) in the aorta of hypercholesterolaemic atherosclerotic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Simvastatin inhibits sPLA2 IIa expression in aorta and myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Differential metabolic effects of distinct statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Anti-inflammatory and monocyte-suppressing effects of simvastatin in patients with impaired fasting glucose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Lymphocyte-suppressing effect of simvastatin in mixed dyslipidemic patients but not impaired glucose tolerance patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Hemostatic effects of simvastatin in subjects with impaired fasting glucose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs--the CEPHEUS-Greece survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

C-reactive protein and coronary heart disease: predictive test or therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Obesity and arterial compliance alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Lipid-lowering drugs acting at the level of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Combination of fenofibrate with non-statin drug regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effect of fenofibrate on uric acid metabolism and urate transporter 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Pleiotropic effects of fenofibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Combination therapy of statins and fibrates in the management of cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Statin-fibrate combination for mixed dyslipidaemia: a limited option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

21 January 2018

Simvastatin: a review

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effects of lifestyle counseling and combination lipid-modifying therapy on lipoprotein-associated phospholipase A2 mass concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Pathophysiology of cerebral ischemia and brain trauma: similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Combination lipid therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effects of medical therapies on retinopathy progression in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Combination statin-fibrate therapy: safety aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Fibrate treatment can increase serum creatinine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Fibrate-induced increase in serum urea and creatinine levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Triglycerides and the Risk of Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: A randomized, double-blind, placebo-controlled, cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.593509

10.1517/14656566.2011.593509

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21736529